Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation

NCT07890181 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2026-09-01
Last updated
2026-10-22

Condition(s) studied

Geographic MismatchShort-TermMajor Adverse Cardiovascular EventsLong Coronary Stent Implantation

Investigational drug(s) / intervention(s)

Coronary Stent Implantation

Coronary Stent Implantation: Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length

Study summary

This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years old. * Both sexes. * Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length. * Successful stent deployment with discharge after PCI. Exclusion Criteria: * Bare-metal stent (BMS) implantation. * Cardiogenic shock at presentation. * In-stent restenosis lesions. * Previous stent implantation in the target coronary segment. * Life expectancy \<6 months due to non-cardiac causes. * Incomplete clinical or geographic data. * Patients lost to follow-up immediately after hospital discharge.

Primary outcome measure(s)

  • Incidence of Major Adverse Cardiovascular Events — 30 days post-percutaneous coronary intervention
    Incidence of Major Adverse Cardiovascular Events (MACE) will be recorded within 30 days post-percutaneous coronary intervention (PCI).

Trial sites (1)

FacilityCityRegionStatus
Sohag University Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07890181 on ClinicalTrials.gov ↗ ← All trials in Egypt